Horizon Pharma PLC (NASDAQ:HZNP) reported Q2 2017 earnings this Morning, coming in at $0.41 per share, beating Wall Street’s estimates of $0.12 per Share. Revenue for the quarter came in at $289.51 million beating analyst estimates of $237.01 million
Analyst Coverage For Horizon Pharma PLC (NASDAQ:HZNP)
These are 2 Hold Ratings, 10 Buy Ratings .
The current consensus rating for Horizon Pharma PLC (NASDAQ:HZNP) is Buy (Score: 2.83) with a consensus target price of $19.33 , a potential (52.23% upside)Recent Insider Trading for Horizon Pharma PLC (NASDAQ:HZNP)
- On 5/10/2017 Michael G Grey, Director, bought 10,000 with an average share price of $9.48 per share and the total transaction amounting to $94,800.00.
- On 3/1/2017 Robert Carey, EVP, sold 31,808 with an average share price of $16.03 per share and the total transaction amounting to $509,882.24.
- On 8/2/2016 Jeffrey W. Sherman, EVP, sold 2,900 with an average share price of $20.00 per share and the total transaction amounting to $58,000.00.
- On 6/15/2016 Virinder Nohria, Director, sold 25,000 with an average share price of $17.69 per share and the total transaction amounting to $442,250.00.
- On 2/26/2016 Jeffrey W Sherman, EVP, sold 4,100 with an average share price of $20.00 per share and the total transaction amounting to $82,000.00.
- On 12/10/2015 Jeffrey W Sherman, EVP, sold 4,456 with an average share price of $20.00 per share and the total transaction amounting to $89,120.00.
Recent Trading for Horizon Pharma PLC (NASDAQ:HZNP) Shares of Horizon Pharma PLC closed the previous trading session at 13.30 up +0.60 4.72% with shares trading hands.